Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum.

The corpus luteum (CL) offers the opportunity to study high proliferative processes during its development and degradation processes during its regression. We examined the mRNA expression of matrix metalloproteases (MMP)-1, MMP-2, MMP-9, MMP-14, MMP-19, tissue inhibitor of MMP (TIMP)-1, TIMP-2, tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), uPA-receptor (uPAR), PA-inhibitors (PAI)-1, PAI-2 in follicles 20 h after GnRH application, CLs during days 1-2, 3-4, 5-7 and 8-12 of the oestrous cycle as well as after induced luteolysis. Cows in the mid-luteal phase were injected with Cloprostenol and the CLs were collected at 0.5, 2, 4, 12, 24, 48 and 64 h after PGF2alpha injection. Real-time RT-PCR determined mRNA expressions. Expression from 20 h after GnRH to day 12: MMP-1, MMP-2, MMP-14 and tPA showed a clear expression, but no regulation. TIMP-1 and uPAR mRNA increased when compared with the follicular phase. TIMP-2, MMP-9, MMP-19 and uPA increased from the follicular phase to days 8-12. PAI-1 and PAI-2 expression increased from days 1-7 and decreased to days 8-12. Induced luteolysis: MMP-1, MMP-2, MMP-9, MMP-14, MMP-19 and TIMP-1 all increased at different time points and intensities, whereas TIMP-2 was constantly decreased from 24 to 64 h. The plasminogen activator system and their inhibitors were up-regulated from 2 to 64 h, tPA was already increased after 0.5 h. Immunohistochemistry for MMP-1, MMP-2, MMP-14: an increased staining for MMP-1 and MMP-14 was seen in large luteal cells beginning 24 h after PGF2alpha application. MMP-2 showed a strong increase in staining in endothelial cells at 48 h.

[1]  B. Berisha,et al.  Expression of estrogen and progesterone receptors in the bovine ovary during estrous cycle and pregnancy , 2007, Endocrine.

[2]  B. Berisha,et al.  Expression of fibroblast growth factor 1 (FGF1) and FGF7 in mature follicles during the periovulatory period after GnRH in the cow. , 2006, The Journal of reproduction and development.

[3]  B. Berisha,et al.  Changes in fibroblast growth factor 2 and its receptors in bovine follicles before and after GnRH application and after ovulation. , 2006, Reproduction.

[4]  M. Moses,et al.  Matrix metalloproteinase‐2 (MMP‐2) expression and regulation by tumor necrosis factor alpha (TNFα) in the bovine corpus luteum , 2005 .

[5]  T. Curry,et al.  Regulation of Matrix Metalloproteinase-19 Messenger RNA Expression in the Rat Ovary1 , 2004, Biology of reproduction.

[6]  J. Byström,et al.  Plasminogen activator inhibitor‐2 (PAI‐2) in eosinophilic leukocytes , 2004, Journal of leukocyte biology.

[7]  B. Berisha,et al.  Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol. , 2004, Reproduction in domestic animals = Zuchthygiene.

[8]  B. Berisha,et al.  Regulation of corpus luteum function in cattle--an overview. , 2004, Reproduction in domestic animals = Zuchthygiene.

[9]  B. Berisha,et al.  Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression during induced luteolysis in the bovine corpus luteum , 2004, Molecular reproduction and development.

[10]  M. Pfaffl,et al.  Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – Excel-based tool using pair-wise correlations , 2004, Biotechnology Letters.

[11]  B. Berisha,et al.  Involvement of Pro-Inflammatory Cytokines, Mediators of Inflammation, and Basic Fibroblast Growth Factor in Prostaglandin F2α-Induced Luteolysis in Bovine Corpus Luteum1 , 2004, Biology of reproduction.

[12]  O. Mueller,et al.  RNA Integrity Number ( RIN ) – Standardization of RNA Quality Control Application , 2004 .

[13]  L. Wahl,et al.  Interferon-γ Differentially Regulates Monocyte Matrix Metalloproteinase-1 and -9 through Tumor Necrosis Factor-α and Caspase 8* , 2003, Journal of Biological Chemistry.

[14]  B. Rueda,et al.  Microvascular endothelial cells of the corpus luteum , 2003, Reproductive biology and endocrinology : RB&E.

[15]  Kui Liu,et al.  Expression and regulation of plasminogen activators, plasminogen activator inhibitor type-1, and steroidogenic acute regulatory protein in the rhesus monkey corpus luteum. , 2003, Endocrinology.

[16]  K. Osteen,et al.  The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. , 2003, Endocrine reviews.

[17]  B. Berisha,et al.  Real‐time changes of the local vasoactive peptide systems (angiotensin, endothelin) in the bovine corpus luteum after induced luteal regression , 2003, Molecular reproduction and development.

[18]  H. Endo,et al.  Stage‐specific regulatory element of mouse Sry gene , 2003, Molecular reproduction and development.

[19]  L. Wahl,et al.  Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-alpha and caspase 8. , 2003, The Journal of biological chemistry.

[20]  W. Murdoch,et al.  Role of matrix metalloproteinase 2 in the ovulatory folliculo-luteal transition of ewes. , 2002, Reproduction.

[21]  R. Stouffer,et al.  Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. , 2002, Molecular human reproduction.

[22]  M. Moses,et al.  Bovine Membrane-Type 1 Matrix Metalloproteinase: Molecular Cloning and Expression in the Corpus Luteum1 , 2002, Biology of reproduction.

[23]  T. Ny,et al.  Matrix remodeling in the ovary: regulation and functional role of the plasminogen activator and matrix metalloproteinase systems , 2002, Molecular and Cellular Endocrinology.

[24]  J Frederick Woessner,et al.  MMPs and TIMPs—An historical perspective , 2002, Methods in molecular biology.

[25]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[26]  J. Laissue,et al.  MMP‐19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours , 2001, The Journal of pathology.

[27]  H. Shimada,et al.  Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. , 2001, Cancer research.

[28]  I. Walter,et al.  Matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitor-2 of matrix metalloproteinases (TIMP-2) in the placenta and interplacental uterine wall in normal cows and in cattle with retention of fetal membranes. , 2001, Placenta.

[29]  R. Rasmussen.  Quantification on the LightCycler , 2001 .

[30]  R. Einspanier,et al.  Expression and localisation of vascular endothelial growth factor and basic fibroblast growth factor during the final growth of bovine ovarian follicles. , 2000, The Journal of endocrinology.

[31]  R. Einspanier,et al.  Expression and Tissue Concentration of Vascular Endothelial Growth Factor, Its Receptors, and Localization in the Bovine Corpus Luteum During Estrous Cycle and Pregnancy1 , 2000, Biology of reproduction.

[32]  R. Forough,et al.  Overexpression of a secretory form of FGF‐1 promotes MMP‐1‐mediated endothelial cell migration , 2000, Journal of cellular biochemistry.

[33]  K. Spanel‐Borowski,et al.  Difference in localization of eosinophils and mast cells in the bovine ovary. , 2000, Journal of reproduction and fertility.

[34]  K. Tanaka,et al.  Signal transduction and transcriptional regulation of angiogenesis. , 2000, Advances in experimental medicine and biology.

[35]  M. F. Smith,et al.  Regulation of ovarian extracellular matrix remodelling by metalloproteinases and their tissue inhibitors: effects on follicular development, ovulation and luteal function. , 2019, Journal of reproduction and fertility. Supplement.

[36]  U. Krawinkel,et al.  Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. , 1999, Experimental cell research.

[37]  M. Luck,et al.  Distribution of extracellular matrix components in the developing ruminant corpus luteum: a wound repair hypothesis for luteinization. , 1999, Journal of reproduction and fertility.

[38]  R. Webb,et al.  Immune cells and cytokine production in the bovine corpus luteum throughout the oestrous cycle and after induced luteolysis. , 1999, Journal of reproduction and fertility.

[39]  L. Wahl,et al.  Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. , 1998, Journal of immunology.

[40]  H. Granger,et al.  Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[41]  E. Keshet,et al.  Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: a mechanism for balancing pericellular proteolysis during angiogenesis. , 1998, Blood.

[42]  A. Reiner,et al.  Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.

[43]  M A Moses,et al.  The regulation of neovascularization of matrix metalloproteinases and their inhibitors. , 1998, Stem cells.

[44]  T. Plesner,et al.  Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR , 1997, Stem cells.

[45]  Y. Sun,et al.  Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter , 1997, Molecular and cellular biology.

[46]  T. Ny,et al.  Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression , 1997, Molecular and Cellular Endocrinology.

[47]  S. Mandriota,et al.  Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. , 1997, Journal of cell science.

[48]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[49]  D. Falcone,et al.  Role of Laminin in Matrix Induction of Macrophage Urokinase-type Plasminogen Activator and 92-kDa Metalloproteinase Expression* , 1997, The Journal of Biological Chemistry.

[50]  Z. Werb,et al.  Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene , 1996, The Journal of cell biology.

[51]  J. Warren,et al.  Expression of monocyte chemoattractant protein-1 in the corpus luteum of the rat. , 1996, Biology of reproduction.

[52]  Liu Yixun,et al.  Studies on the role of plasminogen activators and plasminogen activator inhibitor type-1 in rat corpus luteum of pregnancy. , 1995 .

[53]  M. Luck,et al.  Gene expression and protein distribution of collagen, fibronectin and laminin in bovine follicles and corpora lutea. , 1995, Journal of reproduction and fertility.

[54]  Q. Feng,et al.  Studies on the role of plasminogen activators and plasminogen activator inhibitor type-1 in rat corpus luteum of pregnancy. , 1995, Biology of reproduction.

[55]  M. Gyetko,et al.  Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. , 1994, Blood.

[56]  R. Norman,et al.  Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. , 1994, Fertility and sterility.

[57]  M. F. Smith,et al.  Pattern of protein production by bovine corpora lutea during luteolysis and characterization of expression of two major secretory products of regressing corpora lutea. , 1994, Journal of reproduction and fertility.

[58]  M. Luck,et al.  Identification and measurement of collagen in the bovine corpus luteum and its relationship with ascorbic acid and tissue development. , 1993, Journal of reproduction and fertility.

[59]  Feng Qiang,et al.  The possible involvement of tissue type plasminogen activator in luteolysis of rhesus monkey , 1993 .

[60]  S. Shapiro,et al.  Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. , 1993, The Journal of biological chemistry.

[61]  Q. Feng,et al.  The possible involvement of tissue type plasminogen activator in luteolysis of rhesus monkey. , 1993, Human reproduction.

[62]  E. Bauer,et al.  Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells , 1992, Journal of cellular physiology.

[63]  E. Keshet,et al.  In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[64]  B. Chew,et al.  Quantitative and Qualitative Changes in Blood Leukocytes in the Porcine Ovary , 1991, American journal of reproductive immunology.

[65]  W. Murdoch,et al.  Investigations Concerning the Relationship of Ovarian Eosinophilia to Ovulation and Luteal Function in the Sheep , 1991, American journal of reproductive immunology.

[66]  D. Sugarbaker,et al.  Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. , 1990, Journal of immunology.

[67]  A. Eisen,et al.  Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. , 1990, The Journal of clinical investigation.

[68]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[69]  J. Woessner,et al.  Connective tissue breakdown in ovulation , 1989, Steroids.

[70]  P. Hart,et al.  Human monocytes can produce tissue-type plasminogen activator , 1989, The Journal of experimental medicine.

[71]  H. Remold,et al.  IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. , 1988, Journal of immunology.

[72]  E. Schallenberger,et al.  Development of a sensitive enzymeimmunoassay (EIA) for progesterone determination in unextracted bovine plasma using the second antibody technique. , 1987, Journal of steroid biochemistry.